GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Beneish M-Score

Extrawell Pharmaceutical Holdings (HKSE:00858) Beneish M-Score : -1.86 (As of May. 25, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.86 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's Beneish M-Score or its related term are showing as below:

HKSE:00858' s Beneish M-Score Range Over the Past 10 Years
Min: -3.57   Med: -2.37   Max: -0.04
Current: -1.86

During the past 13 years, the highest Beneish M-Score of Extrawell Pharmaceutical Holdings was -0.04. The lowest was -3.57. And the median was -2.37.


Extrawell Pharmaceutical Holdings Beneish M-Score Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Beneish M-Score Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.20 -1.10 -3.02 -2.09 -1.86

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.09 - -1.86 -

Competitive Comparison of Extrawell Pharmaceutical Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Beneish M-Score falls into.



Extrawell Pharmaceutical Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Extrawell Pharmaceutical Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0911+0.528 * 1.1839+0.404 * 1.0569+0.892 * 0.9818+0.115 * 0.9177
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8557+4.679 * 0.088648-0.327 * 0.9843
=-1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was HK$47.23 Mil.
Revenue was HK$72.58 Mil.
Gross Profit was HK$31.14 Mil.
Total Current Assets was HK$178.66 Mil.
Total Assets was HK$1,444.87 Mil.
Property, Plant and Equipment(Net PPE) was HK$136.54 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$8.80 Mil.
Selling, General, & Admin. Expense(SGA) was HK$42.42 Mil.
Total Current Liabilities was HK$57.01 Mil.
Long-Term Debt & Capital Lease Obligation was HK$101.91 Mil.
Net Income was HK$129.27 Mil.
Gross Profit was HK$0.00 Mil.
Cash Flow from Operations was HK$1.18 Mil.
Total Receivables was HK$44.09 Mil.
Revenue was HK$73.93 Mil.
Gross Profit was HK$37.56 Mil.
Total Current Assets was HK$194.38 Mil.
Total Assets was HK$1,317.10 Mil.
Property, Plant and Equipment(Net PPE) was HK$148.39 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$8.73 Mil.
Selling, General, & Admin. Expense(SGA) was HK$50.50 Mil.
Total Current Liabilities was HK$64.06 Mil.
Long-Term Debt & Capital Lease Obligation was HK$83.11 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(47.232 / 72.577) / (44.092 / 73.925)
=0.650785 / 0.596442
=1.0911

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(37.556 / 73.925) / (31.143 / 72.577)
=0.508028 / 0.429103
=1.1839

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (178.663 + 136.544) / 1444.874) / (1 - (194.382 + 148.39) / 1317.101)
=0.781845 / 0.739753
=1.0569

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=72.577 / 73.925
=0.9818

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(8.727 / (8.727 + 148.39)) / (8.797 / (8.797 + 136.544))
=0.055545 / 0.060527
=0.9177

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(42.421 / 72.577) / (50.498 / 73.925)
=0.584496 / 0.683098
=0.8557

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((101.908 + 57.014) / 1444.874) / ((83.113 + 64.063) / 1317.101)
=0.10999 / 0.111742
=0.9843

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(129.265 - 0 - 1.18) / 1444.874
=0.088648

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Extrawell Pharmaceutical Holdings has a M-score of -1.86 suggests that the company is unlikely to be a manipulator.


Extrawell Pharmaceutical Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines